Value of China’s innovative drug out-licensing deals hit new high in H1
Wire desk byline Sourced from Xinhua, Dawn, Arab News, Anadolu and Minute Mirror. Translated and abridged by the GSRRA Desk.
The total value of China’s innovative drug out-licensing deals exceeded 100 billion U.S. dollars in the first half of the year, reaching a record high, the Ministry of Industry and Information Technology (MIIT) said Monday.
China approved 38 innovative drugs for marketing during the period, including 31 developed by domestic companies, Tao Qing, head of the bureau for operation, monitoring, and coordination with the MIIT, told a media conference.
Despite a complex and challenging external environment and mounting pressure from industry transformation, China’s pharmaceutical industry remained resilient, Tao said.
From January to June, value-added industrial output of major pharmaceutical enterprises rose 6.4 percent year on year, with biopharmaceuticals posting double-digit growth.
The industry’s export delivery value exceeded 210 billion yuan (about 30.91 billion U.S. dollars) in the first six months, up 9 percent from a year earlier.
Higher value-added products, including chemical finished dosage forms and biopharmaceuticals, accounted for nearly one-fifth of total exports, indicating an accelerating shift in the export mix from active pharmaceutical ingredients (APIs) to finished pharmaceutical products.
Reference Link:- https://english.news.cn/20260720/f4f0de6f4d10466abadf953f156cedc8/c.html
Zamir Ahmed Awan is the founder and Chair of the Global Silk Route Research Alliance, a think tank in Islamabad. He studied engineering at Shanghai University in the 1980s, and years later he went back to China as Pakistan's science counsellor in Beijing, from 2010 until 2016, working on science and higher education cooperation between the two countries.…
